Fingolimod for Multiple Sclerosis
- 26 January 2012
- journal article
- review article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 366 (4), 339-347
- https://doi.org/10.1056/nejmct1101691
Abstract
A 37-year-old man with multiple sclerosis has recurrent disease activity despite several previous therapies. Treatment with fingolimod is recommended. Fingolimod blocks the egress of lymphocytes from lymph nodes, preventing them from reaching the central nervous system.This publication has 38 references indexed in Scilit:
- Natural history of secondary-progressive multiple sclerosisMultiple Sclerosis Journal, 2008
- S1P1 Receptor Signaling Overrides Retention Mediated by Gαi-Coupled Receptors to Promote T Cell EgressImmunity, 2008
- Finding a way out: lymphocyte egress from lymphoid organsNature Immunology, 2007
- Costs and quality of life in multiple sclerosisNeurology, 2006
- Multiple sclerosisImmunological Reviews, 2005
- Trends in survival and cause of death in Danish patients with multiple sclerosisBrain, 2004
- The immunosuppressant FTY720 down‐regulates sphingosine 1‐phosphate G protein‐coupled receptorsThe FASEB Journal, 2004
- FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppressionTransplantation Proceedings, 2001
- Life expectancy in patients attending multiple sclerosis clinicsNeurology, 1992
- THE NATURAL HISTORY OF MULTIPLE SCLEROSIS: A GEOGRAPHICALLY BASED STUDYBrain, 1989